APO Research
Talk to an analyst

APO RESEARCH · REPORT

IBS Treatment

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global IBS Treatment Industry Growth and Trends Forecast to 2032

20 December 2025120 pages

Choose your research edition.

Industry ResearchIBS Treatment Industry Research Report 2026145 pages · $2,950 USDIndustry Growth & TrendsGlobal IBS Treatment Industry Growth and Trends Forecast to 2032120 pages · $3,450 USDMarket StructureGlobal IBS Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal IBS Treatment Market Outlook and Growth Opportunities 2026216 pages · $4,250 USDMarket Analysis & ForecastGlobal IBS Treatment Market Analysis and Forecast 2026-2032219 pages · $4,950 USD

Market perspective

According to APO Research, the global IBS Treatment market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for IBS Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for IBS Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for IBS Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global companies in the IBS Treatment market include Takeda Pharmaceutical Company (Japan), Nestle (Switzerland), Novartis (Switzerland), Pfizer (U.S.), Synthetic Biologics (U.S.), Synergy Pharmaceuticals (U.S.), Sucampo Pharmaceuticals (U.S.), Sebela Pharmaceuticals (Ireland) and RedHill Biopharma (Israel), among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global IBS Treatment market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The IBS Treatment market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global IBS Treatment market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to IBS Treatment.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global IBS Treatment market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

IBS Treatment Market by Company

Takeda Pharmaceutical Company (Japan)

Nestle (Switzerland)

Novartis (Switzerland)

Pfizer (U.S.)

Synthetic Biologics (U.S.)

Synergy Pharmaceuticals (U.S.)

Sucampo Pharmaceuticals (U.S.)

Sebela Pharmaceuticals (Ireland)

RedHill Biopharma (Israel)

Protagonist Therapeutics (U.S.)

Probi (Sweden)

Lexicon Pharmaceuticals (U.S.)

Ironwood Pharmaceuticals (U.S.)

Ipsen (France)

Innovate Biopharmaceuticals (U.S.)

Bausch Health

AstraZeneca (U.K)

Astellas Pharma (Japan)

Ardelyx (U.S.)

Allergan (Ireland)

Alfasigma USA (Italy)

Abbott Laboratories (U.S.)

IBS Treatment Segment by Type

IBS-D

IBS-C

IBS-M

IBS Treatment Segment by Application

Hospitals

Clinics

Research Laboratories

IBS Treatment Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global IBS Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of IBS Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of IBS Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of IBS Treatment companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global IBS Treatment Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global IBS Treatment Market Size by Region (2021-2026) & (US$ Million) Table 3. Global IBS Treatment Market Share by Region (2021-2026) Table 4. Global IBS Treatment Market Size by Region (2027-2032) & (US$ Million) Table 5. Global IBS Treatment Market Share by Region (2027-2032) Table 6. Global IBS Treatment Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global IBS Treatment Market Size by Type (2021-2026) & (US$ Million) Table 8. Global IBS Treatment Market Size Share by Type (2021-2026) Table 9. Global IBS Treatment Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global IBS Treatment Market Size Share Forecasted by Type (2027-2032) Table 11. North America IBS Treatment Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America IBS Treatment Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe IBS Treatment Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe IBS Treatment Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific IBS Treatment Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific IBS Treatment Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America IBS Treatment Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America IBS Treatment Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa IBS Treatment Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa IBS Treatment Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global IBS Treatment Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global IBS Treatment Market Size by Application (2021-2026) & (US$ Million) Table 23. Global IBS Treatment Market Size Share by Application (2021-2026) Table 24. Global IBS Treatment Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global IBS Treatment Market Size Share Forecasted by Application (2027-2032) Table 26. North America IBS Treatment Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America IBS Treatment Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe IBS Treatment Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe IBS Treatment Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific IBS Treatment Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific IBS Treatment Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America IBS Treatment Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America IBS Treatment Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa IBS Treatment Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa IBS Treatment Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. IBS Treatment Industry Trends Table 37. IBS Treatment Industry Drivers Table 38. IBS Treatment Industry Opportunities and Challenges Table 39. IBS Treatment Industry Restraints Table 40. Global IBS Treatment Revenue by Company (US$ Million) & (2021-2026) Table 41. Global IBS Treatment Revenue Market Share by Company (2021-2026) Table 42. Global IBS Treatment Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global IBS Treatment Key Company Headquarters & Area Served Table 44. Global IBS Treatment Company, Product Type & Application Table 45. Global IBS Treatment Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global IBS Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. Takeda Pharmaceutical Company (Japan) Company Information Table 49. Takeda Pharmaceutical Company (Japan) Business Overview Table 50. Takeda Pharmaceutical Company (Japan) IBS Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. Takeda Pharmaceutical Company (Japan) IBS Treatment Product Portfolio Table 52. Takeda Pharmaceutical Company (Japan) Recent Development Table 53. Nestle (Switzerland) Company Information Table 54. Nestle (Switzerland) Business Overview Table 55. Nestle (Switzerland) IBS Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. Nestle (Switzerland) IBS Treatment Product Portfolio Table 57. Nestle (Switzerland) Recent Development Table 58. Novartis (Switzerland) Company Information Table 59. Novartis (Switzerland) Business Overview Table 60. Novartis (Switzerland) IBS Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. Novartis (Switzerland) IBS Treatment Product Portfolio Table 62. Novartis (Switzerland) Recent Development Table 63. Pfizer (U.S.) Company Information Table 64. Pfizer (U.S.) Business Overview Table 65. Pfizer (U.S.) IBS Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. Pfizer (U.S.) IBS Treatment Product Portfolio Table 67. Pfizer (U.S.) Recent Development Table 68. Synthetic Biologics (U.S.) Company Information Table 69. Synthetic Biologics (U.S.) Business Overview Table 70. Synthetic Biologics (U.S.) IBS Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. Synthetic Biologics (U.S.) IBS Treatment Product Portfolio Table 72. Synthetic Biologics (U.S.) Recent Development Table 73. Synergy Pharmaceuticals (U.S.) Company Information Table 74. Synergy Pharmaceuticals (U.S.) Business Overview Table 75. Synergy Pharmaceuticals (U.S.) IBS Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. Synergy Pharmaceuticals (U.S.) IBS Treatment Product Portfolio Table 77. Synergy Pharmaceuticals (U.S.) Recent Development Table 78. Sucampo Pharmaceuticals (U.S.) Company Information Table 79. Sucampo Pharmaceuticals (U.S.) Business Overview Table 80. Sucampo Pharmaceuticals (U.S.) IBS Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 81. Sucampo Pharmaceuticals (U.S.) IBS Treatment Product Portfolio Table 82. Sucampo Pharmaceuticals (U.S.) Recent Development Table 83. Sebela Pharmaceuticals (Ireland) Company Information Table 84. Sebela Pharmaceuticals (Ireland) Business Overview Table 85. Sebela Pharmaceuticals (Ireland) IBS Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 86. Sebela Pharmaceuticals (Ireland) IBS Treatment Product Portfolio Table 87. Sebela Pharmaceuticals (Ireland) Recent Development Table 88. RedHill Biopharma (Israel) Company Information Table 89. RedHill Biopharma (Israel) Business Overview Table 90. RedHill Biopharma (Israel) IBS Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 91. RedHill Biopharma (Israel) IBS Treatment Product Portfolio Table 92. RedHill Biopharma (Israel) Recent Development Table 93. Protagonist Therapeutics (U.S.) Company Information Table 94. Protagonist Therapeutics (U.S.) Business Overview Table 95. Protagonist Therapeutics (U.S.) IBS Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 96. Protagonist Therapeutics (U.S.) IBS Treatment Product Portfolio Table 97. Protagonist Therapeutics (U.S.) Recent Development Table 98. Probi (Sweden) Company Information Table 99. Probi (Sweden) Business Overview Table 100. Probi (Sweden) IBS Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 101. Probi (Sweden) IBS Treatment Product Portfolio Table 102. Probi (Sweden) Recent Development Table 103. Lexicon Pharmaceuticals (U.S.) Company Information Table 104. Lexicon Pharmaceuticals (U.S.) Business Overview Table 105. Lexicon Pharmaceuticals (U.S.) IBS Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 106. Lexicon Pharmaceuticals (U.S.) IBS Treatment Product Portfolio Table 107. Lexicon Pharmaceuticals (U.S.) Recent Development Table 108. Ironwood Pharmaceuticals (U.S.) Company Information Table 109. Ironwood Pharmaceuticals (U.S.) Business Overview Table 110. Ironwood Pharmaceuticals (U.S.) IBS Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 111. Ironwood Pharmaceuticals (U.S.) IBS Treatment Product Portfolio Table 112. Ironwood Pharmaceuticals (U.S.) Recent Development Table 113. Ipsen (France) Company Information Table 114. Ipsen (France) Business Overview Table 115. Ipsen (France) IBS Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 116. Ipsen (France) IBS Treatment Product Portfolio Table 117. Ipsen (France) Recent Development Table 118. Innovate Biopharmaceuticals (U.S.) Company Information Table 119. Innovate Biopharmaceuticals (U.S.) Business Overview Table 120. Innovate Biopharmaceuticals (U.S.) IBS Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 121. Innovate Biopharmaceuticals (U.S.) IBS Treatment Product Portfolio Table 122. Innovate Biopharmaceuticals (U.S.) Recent Development Table 123. Bausch Health Company Information Table 124. Bausch Health Business Overview Table 125. Bausch Health IBS Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 126. Bausch Health IBS Treatment Product Portfolio Table 127. Bausch Health Recent Development Table 128. AstraZeneca (U.K) Company Information Table 129. AstraZeneca (U.K) Business Overview Table 130. AstraZeneca (U.K) IBS Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 131. AstraZeneca (U.K) IBS Treatment Product Portfolio Table 132. AstraZeneca (U.K) Recent Development Table 133. Astellas Pharma (Japan) Company Information Table 134. Astellas Pharma (Japan) Business Overview Table 135. Astellas Pharma (Japan) IBS Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 136. Astellas Pharma (Japan) IBS Treatment Product Portfolio Table 137. Astellas Pharma (Japan) Recent Development Table 138. Ardelyx (U.S.) Company Information Table 139. Ardelyx (U.S.) Business Overview Table 140. Ardelyx (U.S.) IBS Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 141. Ardelyx (U.S.) IBS Treatment Product Portfolio Table 142. Ardelyx (U.S.) Recent Development Table 143. Allergan (Ireland) Company Information Table 144. Allergan (Ireland) Business Overview Table 145. Allergan (Ireland) IBS Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 146. Allergan (Ireland) IBS Treatment Product Portfolio Table 147. Allergan (Ireland) Recent Development Table 148. Alfasigma USA (Italy) Company Information Table 149. Alfasigma USA (Italy) Business Overview Table 150. Alfasigma USA (Italy) IBS Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 151. Alfasigma USA (Italy) IBS Treatment Product Portfolio Table 152. Alfasigma USA (Italy) Recent Development Table 153. Abbott Laboratories (U.S.) Company Information Table 154. Abbott Laboratories (U.S.) Business Overview Table 155. Abbott Laboratories (U.S.) IBS Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 156. Abbott Laboratories (U.S.) IBS Treatment Product Portfolio Table 157. Abbott Laboratories (U.S.) Recent Development Table 158. North America IBS Treatment Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 159. North America IBS Treatment Market Size by Country (2021-2026) & (US$ Million) Table 160. North America IBS Treatment Market Share by Country (2021-2026) Table 161. North America IBS Treatment Market Size Forecast by Country (2027-2032) & (US$ Million) Table 162. North America IBS Treatment Market Share Forecast by Country (2027-2032) Table 163. Europe IBS Treatment Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 164. Europe IBS Treatment Market Size by Country (2021-2026) & (US$ Million) Table 165. Europe IBS Treatment Market Share by Country (2021-2026) Table 166. Europe IBS Treatment Market Size Forecast by Country (2027-2032) & (US$ Million) Table 167. Europe IBS Treatment Market Share Forecast by Country (2027-2032) Table 168. Asia-Pacific IBS Treatment Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 169. Asia-Pacific IBS Treatment Market Size by Country (2021-2026) & (US$ Million) Table 170. Asia-Pacific IBS Treatment Market Share by Country (2021-2026) Table 171. Asia-Pacific IBS Treatment Market Size Forecast by Country (2027-2032) & (US$ Million) Table 172. Asia-Pacific IBS Treatment Market Share Forecast by Country (2027-2032) Table 173. Latin America IBS Treatment Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 174. Latin America IBS Treatment Market Size by Country (2021-2026) & (US$ Million) Table 175. Latin America IBS Treatment Market Share by Country (2021-2026) Table 176. Latin America IBS Treatment Market Size Forecast by Country (2027-2032) & (US$ Million) Table 177. Latin America IBS Treatment Market Share Forecast by Country (2027-2032) Table 178. Middle East & Africa IBS Treatment Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 179. Middle East & Africa IBS Treatment Market Size by Country (2021-2026) & (US$ Million) Table 180. Middle East & Africa IBS Treatment Market Share by Country (2021-2026) Table 181. Middle East & Africa IBS Treatment Market Size Forecast by Country (2027-2032) & (US$ Million) Table 182. Middle East & Africa IBS Treatment Market Share Forecast by Country (2027-2032) Table 183. Research Programs/Design for This Report Table 184. Authors List of This Report Table 185. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. IBS Treatment Product Image Figure 3. Global IBS Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global IBS Treatment Market Size (2021-2032) & (US$ Million) Figure 5. Global IBS Treatment Market Share by Region: 2025 VS 2032 Figure 6. Global IBS Treatment Market Share by Region (2021-2032) Figure 7. North America IBS Treatment Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe IBS Treatment Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific IBS Treatment Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America IBS Treatment Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa IBS Treatment Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. IBS-D Image Figure 13. Global IBS-D Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. IBS-C Image Figure 15. Global IBS-C Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. IBS-M Image Figure 17. Global IBS-M Market Size YoY Growth (2021-2032) & (US$ Million) Figure 18. Global IBS Treatment Market Size Overview by Type (2021-2032) & (US$ Million) Figure 19. Global IBS Treatment Market Share by Type 2025 VS 2032 Figure 20. North America IBS Treatment Market Size Share by Type (2021-2032) Figure 21. Europe IBS Treatment Market Size Share by Type (2021-2032) Figure 22. Asia-Pacific IBS Treatment Market Size Share by Type (2021-2032) Figure 23. Latin America IBS Treatment Market Size Share by Type (2021-2032) Figure 24. Middle East and Africa IBS Treatment Market Size Share by Type (2021-2032) Figure 25. Hospitals Image Figure 26. Global Hospitals Market Size YoY Growth (2021-2032) & (US$ Million) Figure 27. Clinics Image Figure 28. Global Clinics Market Size YoY Growth (2021-2032) & (US$ Million) Figure 29. Research Laboratories Image Figure 30. Global Research Laboratories Market Size YoY Growth (2021-2032) & (US$ Million) Figure 31. Global IBS Treatment Market Size Overview by Application (2021-2032) & (US$ Million) Figure 32. Global IBS Treatment Market Share by Application 2025 VS 2032 Figure 33. North America IBS Treatment Market Size Share by Application (2021-2032) Figure 34. Europe IBS Treatment Market Size Share by Application (2021-2032) Figure 35. Asia-Pacific IBS Treatment Market Size Share by Application (2021-2032) Figure 36. Latin America IBS Treatment Market Size Share by Application (2021-2032) Figure 37. Middle East and Africa IBS Treatment Market Size Share by Application (2021-2032) Figure 38. Global Top 5 and 10 IBS Treatment Players Market Share by Revenue in 2025 Figure 39. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 40. North America IBS Treatment Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 41. North America IBS Treatment Market Share by Country: 2021 VS 2025 VS 2032 Figure 42. North America IBS Treatment Market Share by Country (2021-2032) Figure 43. Europe IBS Treatment Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 44. Europe IBS Treatment Market Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe IBS Treatment Market Share by Country (2021-2032) Figure 46. Asia-Pacific IBS Treatment Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 47. Asia-Pacific IBS Treatment Market Share by Country: 2021 VS 2025 VS 2032 Figure 48. Asia-Pacific IBS Treatment Market Share by Country (2021-2032) Figure 49. Latin America IBS Treatment Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Latin America IBS Treatment Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Latin America IBS Treatment Market Share by Country (2021-2032) Figure 52. Middle East & Africa IBS Treatment Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 53. Middle East & Africa IBS Treatment Market Share by Country: 2021 VS 2025 VS 2032 Figure 54. Middle East & Africa IBS Treatment Market Share by Country (2021-2032) Figure 55. Years Considered Figure 56. Research Process Figure 57. Key Executives Interviewed

Scope & coverage.

Types
  • IBS-D
  • IBS-C
  • IBS-M
Applications
  • Hospitals
  • Clinics
  • Research Laboratories
Companies covered
  • Takeda Pharmaceutical Company (Japan)
  • Nestle (Switzerland)
  • Novartis (Switzerland)
  • Pfizer (U.S.)
  • Synthetic Biologics (U.S.)
  • Synergy Pharmaceuticals (U.S.)
  • Sucampo Pharmaceuticals (U.S.)
  • Sebela Pharmaceuticals (Ireland)
  • RedHill Biopharma (Israel)
  • Protagonist Therapeutics (U.S.)
  • Probi (Sweden)
  • Lexicon Pharmaceuticals (U.S.)
  • Ironwood Pharmaceuticals (U.S.)
  • Ipsen (France)
  • Innovate Biopharmaceuticals (U.S.)
  • Bausch Health
  • AstraZeneca (U.K)
  • Astellas Pharma (Japan)
  • Ardelyx (U.S.)
  • Allergan (Ireland)
  • Alfasigma USA (Italy)
  • Abbott Laboratories (U.S.)

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global IBS Treatment Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global IBS Treatment Market Size by Region (2021-2032)
  5. 1.4.1 Global IBS Treatment Market Size by Region (2021-2026)
  6. 1.4.2 Global IBS Treatment Market Size by Region (2027-2032)
  7. 1.5 Key Regions IBS Treatment Market Size (2021-2032)
  8. 1.5.1 North America IBS Treatment Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe IBS Treatment Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific IBS Treatment Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America IBS Treatment Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa IBS Treatment Market Size Growth Rate (2021-2032)
2 IBS Treatment Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 IBS-D
  3. 2.1.2 IBS-C
  4. 2.1.3 IBS-M
  5. 2.2 Global IBS Treatment Market Size by Type
  6. 2.2.1 Global IBS Treatment Market Size Overview by Type (2021-2032)
  7. 2.2.2 Global IBS Treatment Historic Market Size Review by Type (2021-2026)
  8. 2.2.3 Global IBS Treatment Market Size Forecasted by Type (2027-2032)
  9. 2.3 Global IBS Treatment Market Size by Regions
  10. 2.3.1 North America IBS Treatment Market Size Breakdown by Type (2021-2026)
  11. 2.3.2 Europe IBS Treatment Market Size Breakdown by Type (2021-2026)
  12. 2.3.3 Asia-Pacific IBS Treatment Market Size Breakdown by Type (2021-2026)
  13. 2.3.4 South America IBS Treatment Market Size Breakdown by Type (2021-2026)
  14. 2.3.5 Middle East and Africa IBS Treatment Market Size Breakdown by Type (2021-2026)
3 IBS Treatment Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 Hospitals
  3. 3.1.2 Clinics
  4. 3.1.3 Research Laboratories
  5. 3.2 Global IBS Treatment Market Size by Application
  6. 3.2.1 Global IBS Treatment Market Size Overview by Application (2021-2032)
  7. 3.2.2 Global IBS Treatment Historic Market Size Review by Application (2021-2026)
  8. 3.2.3 Global IBS Treatment Market Size Forecasted by Application (2027-2032)
  9. 3.3 Global IBS Treatment Market Size by Regions
  10. 3.3.1 North America IBS Treatment Market Size Breakdown by Application (2021-2026)
  11. 3.3.2 Europe IBS Treatment Market Size Breakdown by Application (2021-2026)
  12. 3.3.3 Asia-Pacific IBS Treatment Market Size Breakdown by Application (2021-2026)
  13. 3.3.4 South America IBS Treatment Market Size Breakdown by Application (2021-2026)
  14. 3.3.5 Middle East and Africa IBS Treatment Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 IBS Treatment Industry Trends
  2. 4.2 IBS Treatment Industry Drivers
  3. 4.3 IBS Treatment Industry Opportunities and Challenges
  4. 4.4 IBS Treatment Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by IBS Treatment Revenue (2021-2026)
  2. 5.2 Global IBS Treatment Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global IBS Treatment Key Company Headquarters & Area Served
  4. 5.4 Global IBS Treatment Company, Product Type & Application
  5. 5.5 Global IBS Treatment Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global IBS Treatment Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 IBS Treatment Players Market Share by Revenue in 2025
  9. 5.6.3 2025 IBS Treatment Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 Takeda Pharmaceutical Company (Japan)
  2. 6.1.1 Takeda Pharmaceutical Company (Japan) Company Information
  3. 6.1.2 Takeda Pharmaceutical Company (Japan) Business Overview
  4. 6.1.3 Takeda Pharmaceutical Company (Japan) IBS Treatment Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 Takeda Pharmaceutical Company (Japan) IBS Treatment Product Portfolio
  6. 6.1.5 Takeda Pharmaceutical Company (Japan) Recent Developments
  7. 6.2 Nestle (Switzerland)
  8. 6.2.1 Nestle (Switzerland) Company Information
  9. 6.2.2 Nestle (Switzerland) Business Overview
  10. 6.2.3 Nestle (Switzerland) IBS Treatment Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 Nestle (Switzerland) IBS Treatment Product Portfolio
  12. 6.2.5 Nestle (Switzerland) Recent Developments
  13. 6.3 Novartis (Switzerland)
  14. 6.3.1 Novartis (Switzerland) Company Information
  15. 6.3.2 Novartis (Switzerland) Business Overview
  16. 6.3.3 Novartis (Switzerland) IBS Treatment Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 Novartis (Switzerland) IBS Treatment Product Portfolio
  18. 6.3.5 Novartis (Switzerland) Recent Developments
  19. 6.4 Pfizer (U.S.)
  20. 6.4.1 Pfizer (U.S.) Company Information
  21. 6.4.2 Pfizer (U.S.) Business Overview
  22. 6.4.3 Pfizer (U.S.) IBS Treatment Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 Pfizer (U.S.) IBS Treatment Product Portfolio
  24. 6.4.5 Pfizer (U.S.) Recent Developments
  25. 6.5 Synthetic Biologics (U.S.)
  26. 6.5.1 Synthetic Biologics (U.S.) Company Information
  27. 6.5.2 Synthetic Biologics (U.S.) Business Overview
  28. 6.5.3 Synthetic Biologics (U.S.) IBS Treatment Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 Synthetic Biologics (U.S.) IBS Treatment Product Portfolio
  30. 6.5.5 Synthetic Biologics (U.S.) Recent Developments
  31. 6.6 Synergy Pharmaceuticals (U.S.)
  32. 6.6.1 Synergy Pharmaceuticals (U.S.) Company Information
  33. 6.6.2 Synergy Pharmaceuticals (U.S.) Business Overview
  34. 6.6.3 Synergy Pharmaceuticals (U.S.) IBS Treatment Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 Synergy Pharmaceuticals (U.S.) IBS Treatment Product Portfolio
  36. 6.6.5 Synergy Pharmaceuticals (U.S.) Recent Developments
  37. 6.7 Sucampo Pharmaceuticals (U.S.)
  38. 6.7.1 Sucampo Pharmaceuticals (U.S.) Company Information
  39. 6.7.2 Sucampo Pharmaceuticals (U.S.) Business Overview
  40. 6.7.3 Sucampo Pharmaceuticals (U.S.) IBS Treatment Revenue, Global Share and Gross Margin (2021-2026)
  41. 6.7.4 Sucampo Pharmaceuticals (U.S.) IBS Treatment Product Portfolio
  42. 6.7.5 Sucampo Pharmaceuticals (U.S.) Recent Developments
  43. 6.8 Sebela Pharmaceuticals (Ireland)
  44. 6.8.1 Sebela Pharmaceuticals (Ireland) Company Information
  45. 6.8.2 Sebela Pharmaceuticals (Ireland) Business Overview
  46. 6.8.3 Sebela Pharmaceuticals (Ireland) IBS Treatment Revenue, Global Share and Gross Margin (2021-2026)
  47. 6.8.4 Sebela Pharmaceuticals (Ireland) IBS Treatment Product Portfolio
  48. 6.8.5 Sebela Pharmaceuticals (Ireland) Recent Developments
  49. 6.9 RedHill Biopharma (Israel)
  50. 6.9.1 RedHill Biopharma (Israel) Company Information
  51. 6.9.2 RedHill Biopharma (Israel) Business Overview
  52. 6.9.3 RedHill Biopharma (Israel) IBS Treatment Revenue, Global Share and Gross Margin (2021-2026)
  53. 6.9.4 RedHill Biopharma (Israel) IBS Treatment Product Portfolio
  54. 6.9.5 RedHill Biopharma (Israel) Recent Developments
  55. 6.10 Protagonist Therapeutics (U.S.)
  56. 6.10.1 Protagonist Therapeutics (U.S.) Company Information
  57. 6.10.2 Protagonist Therapeutics (U.S.) Business Overview
  58. 6.10.3 Protagonist Therapeutics (U.S.) IBS Treatment Revenue, Global Share and Gross Margin (2021-2026)
  59. 6.10.4 Protagonist Therapeutics (U.S.) IBS Treatment Product Portfolio
  60. 6.10.5 Protagonist Therapeutics (U.S.) Recent Developments
  61. 6.11 Probi (Sweden)
  62. 6.11.1 Probi (Sweden) Company Information
  63. 6.11.2 Probi (Sweden) Business Overview
  64. 6.11.3 Probi (Sweden) IBS Treatment Revenue, Global Share and Gross Margin (2021-2026)
  65. 6.11.4 Probi (Sweden) IBS Treatment Product Portfolio
  66. 6.11.5 Probi (Sweden) Recent Developments
  67. 6.12 Lexicon Pharmaceuticals (U.S.)
  68. 6.12.1 Lexicon Pharmaceuticals (U.S.) Company Information
  69. 6.12.2 Lexicon Pharmaceuticals (U.S.) Business Overview
  70. 6.12.3 Lexicon Pharmaceuticals (U.S.) IBS Treatment Revenue, Global Share and Gross Margin (2021-2026)
  71. 6.12.4 Lexicon Pharmaceuticals (U.S.) IBS Treatment Product Portfolio
  72. 6.12.5 Lexicon Pharmaceuticals (U.S.) Recent Developments
  73. 6.13 Ironwood Pharmaceuticals (U.S.)
  74. 6.13.1 Ironwood Pharmaceuticals (U.S.) Company Information
  75. 6.13.2 Ironwood Pharmaceuticals (U.S.) Business Overview
  76. 6.13.3 Ironwood Pharmaceuticals (U.S.) IBS Treatment Revenue, Global Share and Gross Margin (2021-2026)
  77. 6.13.4 Ironwood Pharmaceuticals (U.S.) IBS Treatment Product Portfolio
  78. 6.13.5 Ironwood Pharmaceuticals (U.S.) Recent Developments
  79. 6.14 Ipsen (France)
  80. 6.14.1 Ipsen (France) Company Information
  81. 6.14.2 Ipsen (France) Business Overview
  82. 6.14.3 Ipsen (France) IBS Treatment Revenue, Global Share and Gross Margin (2021-2026)
  83. 6.14.4 Ipsen (France) IBS Treatment Product Portfolio
  84. 6.14.5 Ipsen (France) Recent Developments
  85. 6.15 Innovate Biopharmaceuticals (U.S.)
  86. 6.15.1 Innovate Biopharmaceuticals (U.S.) Company Information
  87. 6.15.2 Innovate Biopharmaceuticals (U.S.) Business Overview
  88. 6.15.3 Innovate Biopharmaceuticals (U.S.) IBS Treatment Revenue, Global Share and Gross Margin (2021-2026)
  89. 6.15.4 Innovate Biopharmaceuticals (U.S.) IBS Treatment Product Portfolio
  90. 6.15.5 Innovate Biopharmaceuticals (U.S.) Recent Developments
  91. 6.16 Bausch Health
  92. 6.16.1 Bausch Health Company Information
  93. 6.16.2 Bausch Health Business Overview
  94. 6.16.3 Bausch Health IBS Treatment Revenue, Global Share and Gross Margin (2021-2026)
  95. 6.16.4 Bausch Health IBS Treatment Product Portfolio
  96. 6.16.5 Bausch Health Recent Developments
  97. 6.17 AstraZeneca (U.K)
  98. 6.17.1 AstraZeneca (U.K) Company Information
  99. 6.17.2 AstraZeneca (U.K) Business Overview
  100. 6.17.3 AstraZeneca (U.K) IBS Treatment Revenue, Global Share and Gross Margin (2021-2026)
  101. 6.17.4 AstraZeneca (U.K) IBS Treatment Product Portfolio
  102. 6.17.5 AstraZeneca (U.K) Recent Developments
  103. 6.18 Astellas Pharma (Japan)
  104. 6.18.1 Astellas Pharma (Japan) Company Information
  105. 6.18.2 Astellas Pharma (Japan) Business Overview
  106. 6.18.3 Astellas Pharma (Japan) IBS Treatment Revenue, Global Share and Gross Margin (2021-2026)
  107. 6.18.4 Astellas Pharma (Japan) IBS Treatment Product Portfolio
  108. 6.18.5 Astellas Pharma (Japan) Recent Developments
  109. 6.19 Ardelyx (U.S.)
  110. 6.19.1 Ardelyx (U.S.) Company Information
  111. 6.19.2 Ardelyx (U.S.) Business Overview
  112. 6.19.3 Ardelyx (U.S.) IBS Treatment Revenue, Global Share and Gross Margin (2021-2026)
  113. 6.19.4 Ardelyx (U.S.) IBS Treatment Product Portfolio
  114. 6.19.5 Ardelyx (U.S.) Recent Developments
  115. 6.20 Allergan (Ireland)
  116. 6.20.1 Allergan (Ireland) Company Information
  117. 6.20.2 Allergan (Ireland) Business Overview
  118. 6.20.3 Allergan (Ireland) IBS Treatment Revenue, Global Share and Gross Margin (2021-2026)
  119. 6.20.4 Allergan (Ireland) IBS Treatment Product Portfolio
  120. 6.20.5 Allergan (Ireland) Recent Developments
  121. 6.21 Alfasigma USA (Italy)
  122. 6.21.1 Alfasigma USA (Italy) Company Information
  123. 6.21.2 Alfasigma USA (Italy) Business Overview
  124. 6.21.3 Alfasigma USA (Italy) IBS Treatment Revenue, Global Share and Gross Margin (2021-2026)
  125. 6.21.4 Alfasigma USA (Italy) IBS Treatment Product Portfolio
  126. 6.21.5 Alfasigma USA (Italy) Recent Developments
  127. 6.22 Abbott Laboratories (U.S.)
  128. 6.22.1 Abbott Laboratories (U.S.) Company Information
  129. 6.22.2 Abbott Laboratories (U.S.) Business Overview
  130. 6.22.3 Abbott Laboratories (U.S.) IBS Treatment Revenue, Global Share and Gross Margin (2021-2026)
  131. 6.22.4 Abbott Laboratories (U.S.) IBS Treatment Product Portfolio
  132. 6.22.5 Abbott Laboratories (U.S.) Recent Developments
7 North America
  1. 7.1 North America IBS Treatment Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America IBS Treatment Market Size by Country (2021-2026)
  3. 7.3 North America IBS Treatment Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe IBS Treatment Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe IBS Treatment Market Size by Country (2021-2026)
  3. 8.3 Europe IBS Treatment Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific IBS Treatment Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific IBS Treatment Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific IBS Treatment Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America IBS Treatment Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America IBS Treatment Market Size by Country (2021-2026)
  3. 10.3 South America IBS Treatment Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa IBS Treatment Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa IBS Treatment Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa IBS Treatment Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst